Radius Health, Inc. - 10-K filing on 2015-03-10

Research Agreements (Details)	0 Months Ended		12 Months Ended							12 Months Ended		1 Months Ended		1 Months Ended				12 Months Ended											1 Months Ended		12 Months Ended							0 Months Ended	12 Months Ended		12 Months Ended			0 Months Ended
Research Agreements (Details)	Oct. 07, 2014	Jun. 11, 2014	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2014 Series A-5 Convertible Preferred Stock	Dec. 31, 2013 Series A-5 Convertible Preferred Stock	Dec. 31, 2014 Series A-6 Convertible Preferred Stock	Dec. 31, 2013 Series A-6 Convertible Preferred Stock	Dec. 31, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study Maximum USD ($) item	Dec. 31, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study Maximum EUR (€)	Mar. 31, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study Nordic USD ($) item	Dec. 31, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study Nordic USD ($)	Feb. 28, 2013 Clinical Trial Services Agreement Abaloparatide-TD Phase 2 Clinical Study Nordic Maximum USD ($)	Feb. 28, 2013 Clinical Trial Services Agreement Abaloparatide-TD Phase 2 Clinical Study Nordic Maximum EUR (€)	Feb. 28, 2013 Clinical Trial Services Agreement Abaloparatide-TD Phase 2 Clinical Study Nordic Series A-6 Convertible Preferred Stock Maximum USD ($)	Dec. 31, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Nordic USD ($)	Dec. 31, 2014 Clinical Trial Services Agreement Pass-through costs USD ($)	Dec. 31, 2013 Clinical Trial Services Agreement Pass-through costs USD ($)	Dec. 31, 2012 Clinical Trial Services Agreement Pass-through costs USD ($)	Dec. 31, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study Per patient costs for enrolled patients USD ($)	Dec. 31, 2013 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study Per patient costs for enrolled patients USD ($)	Dec. 31, 2012 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Study Per patient costs for enrolled patients USD ($)	Dec. 31, 2014 Clinical Trial Services Agreement Abaloparatide-TD Phase 2 Clinical Study Per patient costs for enrolled patients	Dec. 31, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Per patient costs for enrolled patients USD ($)	Dec. 31, 2013 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Per patient costs for enrolled patients USD ($)	Dec. 31, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Maximum Per patient costs for enrolled patients	Dec. 31, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Minimum Per patient costs for enrolled patients	Feb. 28, 2013 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Maximum USD ($)	Feb. 28, 2013 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Maximum EUR (€)	Dec. 31, 2014 Clinical Trial Services Agreement Work Statement NB-2 Abaloparatide-TD Phase 2 Clinical Study Per patient costs for enrolled patients USD ($)	Dec. 31, 2013 Clinical Trial Services Agreement Work Statement NB-2 Abaloparatide-TD Phase 2 Clinical Study Per patient costs for enrolled patients USD ($)	Dec. 31, 2012 Clinical Trial Services Agreement Work Statement NB-2 Abaloparatide-TD Phase 2 Clinical Study Per patient costs for enrolled patients USD ($)	Dec. 31, 2012 Clinical Trial Services Agreement Work Statement NB-2 Abaloparatide-TD Phase 2 Clinical Study Preperatory and other start-up costs USD ($)	Dec. 31, 2014 Clinical Trial Services Agreement NB-3 Amendment Nordic Series A-6 Convertible Preferred Stock Maximum USD ($)	Dec. 31, 2014 Clinical Trial Services Agreement NB-3 Amendment Nordic Series A-6 Convertible Preferred Stock Maximum EUR (€)	Dec. 31, 2014 Clinical Trial Services Agreement NB-3 Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Series A-6 Convertible Preferred Stock Maximum USD ($)	May 17, 2011 Clinical Trial Services Agreement Stock Issuance Agreement Nordic Series A-5 Convertible Preferred Stock Former Operating Company	Dec. 31, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Nordic Series A-6 Convertible Preferred Stock USD ($) item	Mar. 31, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Nordic Series A-6 Convertible Preferred Stock	Dec. 31, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Nordic Series A-6 Convertible Preferred Stock Maximum USD ($)	Dec. 31, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Nordic Series A-6 Convertible Preferred Stock Maximum EUR (€)	Dec. 31, 2013 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-TD Phase 2 Clinical Study Nordic Series A-6 Convertible Preferred Stock	Mar. 04, 2014 Clinical Trial Services Agreement Letter of Intent Abaloparatide-SC Phase 3 Extension Clinical Study Nordic
Research Agreements
Final payments, number of euro-denominated installments										2	2
Final payments, number of U.S dollar-denominated installments										2	2
Amount of additional performance incentive payable to every specified patient												$ 500,000
Number of patients to whom additional performance incentive is payable												50
Maximum aggregate amount of additional payments										5,000,000
Amount of euro-denominated payments required over the course of Clinical Trial										49,800,000	41,200,000			4,400,000	3,600,000														9,100,000	7,500,000
Amount of U.S. dollar-denominated payments required over the course of Clinical Trial										3,200,000				300,000															1,100,000
Period for which research and development expense is recognized																					20 months			9 months			19 months	9 months
Research and development expense			45,719,000	60,536,000	54,961,000													1,300,000	3,900,000	6,000,000	8,200,000	31,600,000	30,800,000		9,600,000	4,500,000					0	4,100,000	1,400,000	900,000
Amount reflected in accrued expenses and other current liabilities resulting from services payable in cash													5,600,000				5,900,000
Aggregate value of quarterly stock dividends, payable in shares																2,900,000																			9,100,000	7,500,000					44,500,000	36,800,000
Stock dividends declared																																							29
Number of shares issued						0	6,443	0	496,111																														186,847				32,215
Payments owed to be changed from the right to receive stock to the right to receive cash payment, if an IPO occurs prior to May 31, 2014																																							4,300,000
Number of equal monthly installments for cash payments																																							10
Amount of equal monthly installments for cash payments																																							430,000
Initial term provided for standard-of-care treatment study																																												6
Additional term provided for standard-of-care treatment																																												18 months
Dividend declared (in shares)																																								186,847			32,215
Shares sold	2,750,000	6,500,000
Number of shares exchanged in the Merger																																						6,443
Aggregate U.S. dollar value of quarterly stock dividends, payable in shares																																					$ 800,000
Number of shares due to the counter party																																											32,215